Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection | Zendy

Roy M. Gulick | Zendy; Heather J. Ribaudo | Zendy; Cecilia M. Shikuma | Zendy; Stephanie Lustgarten | Zendy; Kathleen Squires | Zendy; William A. Meyer | Zendy; Edward P. Acosta | Zendy; Bruce R. Schackman | Zendy; Christopher D. Pilcher | Zendy; Robert L. Murphy | Zendy; William E. Maher | Zendy; Mallory D. Witt | Zendy; Richard C. Reichman | Zendy; Sally Snyder | Zendy; Karin L. Klingman | Zendy; Daniel R. Kuritzkes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

Author(s) -

Roy M. Gulick,

Heather J. Ribaudo,

Cecilia M. Shikuma,

Stephanie Lustgarten,

Kathleen Squires,

William A. Meyer,

Edward P. Acosta,

Bruce R. Schackman,

Christopher D. Pilcher,

Robert L. Murphy,

William E. Maher,

Mallory D. Witt,

Richard C. Reichman,

Sally Snyder,

Karin L. Klingman,

Daniel R. Kuritzkes

Publication year - 2004

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa031772

Subject(s) - medicine , efavirenz , human immunodeficiency virus (hiv) , virology , nucleoside , nucleoside analogue , reverse transcriptase inhibitor , pharmacology , sida , viral load , antiretroviral therapy , viral disease , chemistry , stereochemistry

Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, but data from direct comparisons are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research